Savara, Inc. (SVRA): Price and Financial Metrics
GET POWR RATINGS... FREE!
SVRA Stock Price Chart Interactive Chart >
SVRA Price/Volume Stats
| Current price | $2.39 | 52-week high | $2.82 |
| Prev. close | $2.52 | 52-week low | $1.02 |
| Day low | $2.39 | Volume | 117,500 |
| Day high | $2.54 | Avg. volume | 334,112 |
| 50-day MA | $1.86 | Dividend yield | N/A |
| 200-day MA | $1.54 | Market Cap | 272.57M |
Savara, Inc. (SVRA) Company Bio
Savara Inc., a clinical-stage specialty pharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. The company is based in Austin, Texas.
Latest SVRA News From Around the Web
Below are the latest news stories about SAVARA INC that investors may wish to consider to help them evaluate SVRA as an investment opportunity.
Why Shares of Savara Soared This WeekThe clinical-stage biopharmaceutical company focuses on therapies to treat rare respiratory diseases. |
Savara Announces New Employment Inducement GrantAUSTIN, Texas, January 20, 2023--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees. |
Private equity firms are Savara Inc.'s (NASDAQ:SVRA) biggest owners and were rewarded after market cap rose by US$25m last weekIf you want to know who really controls Savara Inc. ( NASDAQ:SVRA ), then you'll have to look at the makeup of its... |
H.C. Wainwright Reaffirms Their Buy Rating on Savara (SVRA)In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Savara (SVRA - Research Report), with a price target of $3.00. The company's shares closed last Friday at $1.17.Fein covers the Healthcare sector, focusing on stocks such as Unity Biotechnology, Wave Life Sciences, and ACADIA Pharmaceuticals. According to TipRanks, Fein has an average return of -10.6% and a 35.48% success rate on recommended stocks. Currently, the analyst consensus on Savara is a Moderate Buy with an average price target of $3.00. |
Savara Reports Third Quarter 2022 Financial Results and Provides Business UpdateAUSTIN, Texas, November 10, 2022--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the third quarter ending September 30, 2022 and provided a business update. |
SVRA Price Returns
| 1-mo | 37.36% |
| 3-mo | 104.27% |
| 6-mo | 39.77% |
| 1-year | 89.68% |
| 3-year | 9.63% |
| 5-year | -79.57% |
| YTD | 54.19% |
| 2022 | 25.00% |
| 2021 | 7.83% |
| 2020 | -74.33% |
| 2019 | -40.82% |
| 2018 | -48.99% |
Loading social stream, please wait...